Rapamycin Regulates iTreg Function through CD39 and Runx1 Pathways

Yunjie Lu, Jirong Wang, Jian Gu, Hao Lu, Xiangcheng Li, Xiaofeng Qian, Xiaoshan Liu, Xuehao Wang, Feng Zhang, Ling LuJournal of Immunology Research 2014 · DOI

TL;DR

This study reveals that rapamycin, an immunosuppressive drug, enhances the function of induced regulatory T cells (iTregs) by upregulating CD39 and Runx1. This finding offers a new perspective on how rapamycin boosts iTreg activity and suggests CD39 as a potential marker for identifying these potent immune-suppressing cells.

What Problem Does This Paper Address?

Regulatory T cells (Tregs) are crucial for maintaining immune system balance and preventing autoimmune diseases. Induced Tregs (iTregs), which can be generated from naive T cells, are a promising therapeutic tool due to their proliferative capacity. However, their clinical application is limited by the difficulty in expanding and precisely identifying them. Rapamycin is known to boost Treg function, but the underlying molecular mechanisms, particularly concerning specific markers like CD39 and transcription factors like Runx1, were not fully understood. This paper aims to elucidate how rapamycin influences the CD39 and Runx1 pathways in human iTregs, thereby enhancing their suppressive capabilities.

Methods

The researchers utilized a combination of standard and advanced immunological techniques:

  • Cell Isolation and Culture: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors. Naive CD4+ T cells were then purified using MACS technology. These naive cells were differentiated into iTregs in vitro using a cocktail of cytokines (IL-2, TGF-β) and, in some conditions, rapamycin.
  • Flow Cytometry: This was a primary tool for analyzing cell populations. Cells were stained with fluorescently labeled antibodies to identify and quantify specific cell surface markers (CD4, CD25, CD39, CD127) and intracellular markers (FoxP3). This allowed for the characterization of Treg subsets and the assessment of marker expression levels.
  • Real-Time PCR (RT-PCR): This technique was used to measure the mRNA levels of specific genes, namely Adenosine Deaminase (ADA) and Runx1, to understand their transcriptional regulation under different treatment conditions.
  • Suppressive Assays: To directly assess the functional capacity of the generated iTregs, CFSE-based co-culture assays were performed. In these assays, iTregs were co-cultured with activated T cells (labeled with CFSE), and the degree of T cell proliferation inhibition was measured to quantify the suppressive activity.

Datasets

Not discussed in the paper. The study utilized primary human peripheral blood samples from healthy adult volunteers.

Key Insights and Ideas

  • CD39 as a Treg Correlate: The study strongly suggests that CD39 expression is not just present on Tregs but is positively correlated with FoxP3 expression, a key Treg transcription factor. This implies CD39 could be a reliable indicator of Treg identity and function.
  • Rapamycin's Dual Action: Rapamycin not only boosts FoxP3 expression but also significantly enhances the expression of CD39 and Runx1 in iTregs. This points to a multi-faceted mechanism by which rapamycin exerts its immunosuppressive effects.
  • Runx1's Central Role: The findings highlight Runx1 as a critical mediator in this process. Its upregulation by rapamycin, alongside CD39, appears to be a key driver of enhanced iTreg suppressive function.
  • CD39 as a Novel Sorting Marker: The identification of CD39+ iTregs exhibiting stronger FoxP3 expression suggests that CD39 could serve as a valuable marker for enriching and isolating functional iTreg populations for therapeutic purposes.

Key Results

  • CD39 and FoxP3 Correlation: Over 30% of CD4+ T cells in human peripheral blood were CD39 positive, and these cells showed higher FoxP3 expression. More than 70% of CD4+CD25+FoxP3+ Tregs were CD39 positive.
  • Rapamycin Enhances iTreg Generation: Rapamycin significantly increased the percentage of FoxP3-expressing iTregs, particularly a FoxP3-high subset, from 13.6% to 27.8%.
  • Improved Suppressive Activity: Rapamycin-treated iTregs demonstrated significantly enhanced suppressive activity compared to iTregs cultured without rapamycin, especially at higher Treg:PBMC ratios.
  • Upregulation of CD39 and Runx1: Rapamycin treatment led to a substantial increase in CD39 expression on iTregs, reaching nearly 70% in some conditions. Furthermore, mRNA levels of both ADA and Runx1 were significantly upregulated by rapamycin.
  • CD39+ iTregs are More Potent: CD39+ iTregs, particularly the CD39+CD127- subset, exhibited higher CD25 and FoxP3 expression compared to their CD39- counterparts.

Limitations and Future Work

  • Mechanism of Runx1 Regulation: While the study shows rapamycin upregulates Runx1, the precise molecular mechanism by which rapamycin influences Runx1 and its interaction with the CD39 pathway requires further investigation. The authors note that Runx1's role in balancing FoxP3 and IL-17 generation is complex and warrants more research.
  • In Vivo Validation: The study primarily focuses on in vitro experiments. Future work should aim to validate these findings in in vivo models to confirm the therapeutic potential of rapamycin-induced CD39+ iTregs in treating autoimmune diseases.
  • Broader Clinical Application: While CD39 is proposed as a novel marker for Treg sorting, further studies are needed to establish its utility and reliability in diverse clinical settings and for large-scale Treg expansion.
  • ADA's Role: The study observed a slight increase in ADA mRNA with rapamycin. Further exploration into the precise role of ADA in this rapamycin-mediated Treg enhancement is warranted.

Summary updated

Abstract

It has been shown that rapamycin is able to significantly increase the expression of FoxP3 and suppress activity in induced Treg (iTreg) cells in vivo and in vitro. CD39 is a newly determined Treg marker that relates to cell suppression. Runx1, a regulator of FoxP3, controls the expression of adenosine deaminase (ADA) gene, which is found recently in the downstream of CD39 pathway in trophoblast cells. Whether rapamycin would influence CD39 pathway and regulate the expression of Runx1 remains to be determined. The addition of rapamycin to human CD4(+) naïve cells in the presence of IL-2, TGF-β promotes the expression of FoxP3. In this paper, we found that CD39 positively correlated with the FoxP3 expression in iTreg cells. Rapamycin induced iTreg cells showed a stronger CD39/Runx1 expression with the enhanced suppressive function. These data suggested that CD39 expression was involved in iTreg generation and the enhanced suppressive ability of rapamycin induced Treg was partly due to Runx1 pathway. We conclude that rapamycin favors CD39/Runx1 expression in human iTreg and provides a novel insight into the mechanisms of iTreg generation enhanced by rapamycin.
BibTeX
@article{lu2014rapamycin,
  author = {Yunjie Lu and Jirong Wang and Jian Gu and Hao Lu and Xiangcheng Li and Xiaofeng Qian and Xiaoshan Liu and Xuehao Wang and Feng Zhang and Ling Lu},
  title = {{Rapamycin Regulates iTreg Function through CD39 and Runx1 Pathways}},
  journal = {Journal of Immunology Research},
  year = {2014},
  doi = {10.1155/2014/989434},
}
Figure